/
Entera is a clinical stage company focused on developing first-in-class oral tablet formats of peptides or protein replacement therapies. We concentrate on underserved, chronic medical conditions for which oral administration of a protein therapy has the potential to significantly shift a treatment paradigm.
The business is unprofitable at the operating level (-27450.00% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 76.8% YoY. Margins deteriorated 22154.4pp alongside, both lines moving the wrong way.
ROIC dropped from -79.17% to -83.01%, capital efficiency is deteriorating. Negative free cash flow of -$7M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$0.00
▼ -76.8% YoY
Net Income (TTM)
-$12M
▼ -19.9% YoY
Op. Margin
-27450.00%
▼ -22154.4pp YoY
ROIC
-68.57%
▼ -3.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$9M
▼ -9.6% YoY
Op. Cash Flow (TTM)
-$9M
▼ -8.1% YoY
Net Debt
-$4M
Net Cash Position
Cash & Equiv.
$4M
5Y CAGR: -35.1%
Continue Research